Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
PDS Biotechnology Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PDSB
Nasdaq
8731
https://www.pdsbiotech.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for PDS Biotechnology Corp
PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions
- Mar 30th, 2024 12:35 pm
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript
- Mar 28th, 2024 2:24 pm
Q4 2023 PDS Biotechnology Corp Earnings Call
- Mar 28th, 2024 3:33 am
PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update
- Mar 27th, 2024 12:51 pm
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
- Mar 27th, 2024 11:30 am
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
- Mar 20th, 2024 12:00 pm
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
- Mar 13th, 2024 2:55 pm
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
- Mar 13th, 2024 12:00 pm
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
- Jan 22nd, 2024 9:45 pm
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
- Jan 16th, 2024 1:00 pm
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
- Jan 2nd, 2024 5:00 pm
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Dec 4th, 2023 9:50 pm
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
- Nov 28th, 2023 12:30 pm
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call Transcript
- Nov 15th, 2023 6:03 pm
PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ...
- Nov 14th, 2023 5:19 pm
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 14th, 2023 12:30 pm
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
- Nov 9th, 2023 1:00 pm
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
- Nov 7th, 2023 1:00 pm
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
- Oct 23rd, 2023 12:00 pm
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
- Oct 11th, 2023 12:00 pm
Scroll